期刊文献+

人胃肠道间质瘤细胞株的建立及其生物学特性

Establishment and characteristics of cell lines from human gastrointestinal stromal tumors
原文传递
导出
摘要 目的从手术切除的人胃肠道问质瘤组织中建立间质瘤细胞株,并探讨其生物学特性。方法将胃肠间质瘤组织切成小块,置于含20%胎牛血清(FBS)的RPMI1640培养基中进行培养,待细胞达80%-90%融合后消化传代培养,并进行形态学、免疫荧光、免疫组织化学、Westernblot及流式细胞术等生物学特性研究。结果成功建立胃肠道问质瘤(GIST)细胞株,该细胞株可在体外培养生存1个月,传代7—8代。经流式细胞仪的免疫荧光分析显示该细胞:CD117+CD34+。且所建立的GIST细胞表达c-kil蛋白,ST1571抑制所建立的GIST细胞增殖。结论间质瘤细胞株可在体外长期培养,且具有明显的间质瘤细胞特征。 Objective To establish the cell lines from specimens of surgically resected human gas- trointestihal stromal tumors (GIST) and to identify their biological characters. Methods The tumor tissues from human GIST were cultured in RPMI 1640 media supplemented with 20% fetal bovine serum. After growing to 80%-90% confluence, the cells were detached for subculture and their characteristics, inclu- ding morphology, immunofluorescence staining, immunohistochemical analysis, Western bloting and flow cytometry were determined. Results GIST cells were successfully established. The cell line was passaged for about 7-8 times in one mouth. Immunofluosescence statining showed CD117 + CD34+. Moreover, the GIST cell lines expressed c-kit protein, and STI571 inhibited the proliferation of the GIST cell lines. Conclusion The GIST cell line was successfully established in vitro and had specific biological characters of GIST.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2013年第6期1252-1254,共3页 Chinese Journal of Experimental Surgery
基金 湖北省自然科学基金资助项目(2010CDB09202)
关键词 胃肠道间质瘤 细胞培养 生物学特性 Gastrointestihal stromal tumors Cell culture Biological characters
  • 相关文献

参考文献14

  • 1Tuveson DA, Willis NA, Jacks T,et al. STI571 inactivation of the gas- trointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene ,2001,20:5054-5058. 被引量:1
  • 2Taguchi T, Sonobe H, Toyonaga S, et al. Conventional and molecular cytogenetic characterization of a new human cell line, GIST - T1, es- tablished from gastrointestinal stromal tumor. Lab Invest, 2002,82: 663 -665. 被引量:1
  • 3Laurini JA, Carter JE. Gastrointestinal stromal tumor: a review of the literature. Arch Pathol Lab Med ,2010,134 : 134-141. 被引量:1
  • 4Nilsson BP, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical coarse, and prog- nostication in the preimatinib mesylate era. Cancer, 2005,103:821- 829. 被引量:1
  • 5Hirota S,Isozaki K, Moriyama Y, et al. Gain-of-function nmtations of c-kit in human gastrointestinal stromal tumors. Science, 1998,279: 577-$80. 被引量:1
  • 6Heinrieh MC, Corless CL, Duensing A, et al. PDGFRA activating mu- tations in gastrointestinal stromal tumors. Science, 2003,299 : 708- 710. 被引量:1
  • 7祃栋赫,张军.胃肠道间质瘤c-kit和PDGFRA基因突变检测及临床诊断意义[J].中华实验外科杂志,2011,28(3):370-372. 被引量:5
  • 8Georgios S, Papaetis KN. Targeted therapy for gastrointestinal stromal tumors : current status and future pepectives. Cancer Metastasis Rev, 2010,29 : 151-170. 被引量:1
  • 9郑松,王昊,冷建杭,童文娟,陶德友,潘月龙.Imatinib耐药的胃肠道间质瘤细胞系的建立及其生物学特征鉴定[J].中华实验外科杂志,2012,29(3):550-551. 被引量:3
  • 10刘景磊,秦净,姚礼庆,侯英勇,孙益红,沈坤堂,束平.胃肠道间质瘤Imatinib耐药细胞株的建立及其生物学特性[J].中华实验外科杂志,2011,28(3):367-369. 被引量:3

二级参考文献60

  • 1Lasota J,Dansonka-Mieszkowska A,Sobin LH,et al.A great iliaority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.Lab Invest,2004,84:874-883. 被引量:1
  • 2Mechtersheimer G,Egerer G,Hensel M,et al.Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib.Virchows Arch,2004,444:108-118. 被引量:1
  • 3Rankin C,Von Mehren M,Blanke C,et al.Dose effect of imatinib (IM) in patients (pts) with metastatic GIST-Phase Ⅲ Sarcoma Group Study S0033.Journal of Clinical oncology,2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition),2004,22(14S):9005. 被引量:1
  • 4Heinrich MC,Corless CL,Blanke CD,et al.Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.J Clin 0ncol,2006,24:4764-4774. 被引量:1
  • 5Debiec-Rychter M,Sciot R,Le Cesne A,et al.KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.Eur J Cancer,2006,42:1093-1103. 被引量:1
  • 6Verweij J,Casali PG,Zalcberg J,et al.Progression-free survival in gastrointestinal stromal tumors with high-dose i matinib:randomized trial.Lancet,2004,39:1127-1134. 被引量:1
  • 7Cristina R,Peter B,Tianhua G,et al.Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.Cancer Ther,2005,11:4182-4190. 被引量:1
  • 8Taguchi T,Sonobe H,Toyonaga S,et al.Conventional and molecular cytogenetic characterization of a new human cell line,GIST-T1,established from gastrointestinal stromal tumor.Laboratory Investigation,2002,82:663-665. 被引量:1
  • 9Tuveson DA,Willis NA,Jacks T,et al.STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein:biological and clinical implications.Oncogene,2001,20:5054-5058. 被引量:1
  • 10Fletcher CD,Berman JJ,Corless C,et al.Diagnosis of gastrointestinal stromal tumors:a consensus approach.Hum Pathol,2002,33:459-465. 被引量:1

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部